Glycerol phenylbutyrate: Phase IV started

Hyperion began the open-label, U.S. Phase IV HPN-100-009 trial to evaluate oral Ravicti 3-6 times per day for 6-24 months in about 24 patients ages <2. Hyperion said the study is a postmarketing requi...